Temsirolimus
Childhood Leiomyosarcoma
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Childhood Leiomyosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
Cixutumumab National Cancer Institute (NCI) | Phase 2 | B |
vx-970 Massachusetts General Hospital | Phase 2 | B |
Cediranib University Health Network, Toronto | Phase 2 | CCC |
Tabelecleucel Pierre Fabre Medicament | Phase 2 | CCC |
View all 26 →
Same molecule, other indications
Temsirolimus is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →